组蛋白去乙酰化酶与癌症。
Histone deacetylases and cancer.
机构信息
Cellular Differentiation Group, Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Av. Gran Via s/n km 2.7, 08908 L'Hospitalet, Barcelona, Spain.
出版信息
Mol Oncol. 2012 Dec;6(6):579-89. doi: 10.1016/j.molonc.2012.07.003. Epub 2012 Aug 27.
Abstract
Reversible acetylation of histone and non-histone proteins is one of the most abundant post-translational modifications in eukaryotic cells. Protein acetylation and deacetylation are achieved by the antagonistic actions of two families of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs). Aberrant protein acetylation, particularly on histones, has been related to cancer while abnormal expression of HDACs has been found in a broad range of cancer types. Therefore, HDACs have emerged as promising targets in cancer therapeutics, and the development of HDAC inhibitors (HDIs), a rapidly evolving area of clinical research. However, the contributions of specific HDACs to a given cancer type remain incompletely understood. The aim of this review is to summarize the current knowledge concerning the role of HDACs in cancer with special emphasis on what we have learned from the analysis of patient samples.
摘要
组蛋白和非组蛋白蛋白质的可逆乙酰化是真核细胞中最丰富的翻译后修饰之一。蛋白质乙酰化和去乙酰化是通过两组酶的拮抗作用实现的，即组蛋白乙酰转移酶（HATs）和组蛋白去乙酰化酶（HDACs）。异常的蛋白质乙酰化，特别是组蛋白上的乙酰化，与癌症有关，而在广泛的癌症类型中发现了 HDAC 的异常表达。因此，HDAC 已成为癌症治疗的有前途的靶点，HDAC 抑制剂（HDIs）的开发是临床研究的一个迅速发展的领域。然而，特定的 HDAC 对特定癌症类型的贡献仍不完全清楚。本综述的目的是总结目前关于 HDAC 在癌症中的作用的知识，特别强调从对患者样本的分析中所学到的内容。
相似文献
1
Histone deacetylases and cancer.组蛋白去乙酰化酶与癌症。
Mol Oncol. 2012 Dec;6(6):579-89. doi: 10.1016/j.molonc.2012.07.003. Epub 2012 Aug 27.
2
HDAC Inhibitors.组蛋白去乙酰化酶抑制剂
Methods Mol Biol. 2016;1436:281-303. doi: 10.1007/978-1-4939-3667-0_19.
3
The role of histone deacetylases (HDACs) in human cancer.组蛋白去乙酰化酶（HDACs）在人类癌症中的作用。
Mol Oncol. 2007 Jun;1(1):19-25. doi: 10.1016/j.molonc.2007.01.001. Epub 2007 Mar 7.
4
Inhibition of histone acetylation and deacetylation enzymes affects longevity, development, and fecundity in the pea aphid (Acyrthosiphon pisum).组蛋白乙酰化和去乙酰化酶的抑制作用影响豌豆蚜（Acyrthosiphon pisum）的寿命、发育和繁殖力。
Arch Insect Biochem Physiol. 2020 Mar;103(3):e21614. doi: 10.1002/arch.21614. Epub 2019 Sep 9.
5
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.组蛋白去乙酰化酶、组蛋白去乙酰化作用与基因转录：从分子生物学到癌症治疗学
Cell Res. 2007 Mar;17(3):195-211. doi: 10.1038/sj.cr.7310149.
6
Deacetylation of Transcription Factors in Carcinogenesis.转录因子在癌症发生中的去乙酰化作用。
Int J Mol Sci. 2021 Oct 30;22(21):11810. doi: 10.3390/ijms222111810.
7
Histone acetylation modifiers in the pathogenesis of malignant disease.组蛋白乙酰化修饰因子在恶性疾病发病机制中的作用
Mol Med. 2000 Aug;6(8):623-44.
8
The emerging roles of HDACs and their therapeutic implications in cancer.组蛋白去乙酰化酶（HDACs）的新兴作用及其在癌症治疗中的意义。
Eur J Pharmacol. 2022 Sep 15;931:175216. doi: 10.1016/j.ejphar.2022.175216. Epub 2022 Aug 18.
9
Histone deacetylases and cancer.组蛋白去乙酰化酶与癌症。
Oncogene. 2007 Aug 13;26(37):5420-32. doi: 10.1038/sj.onc.1210610.
10
Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.使用组蛋白去乙酰化酶抑制剂分析组蛋白去乙酰化酶与翻译的相关性。
Methods Mol Biol. 2017;1510:77-91. doi: 10.1007/978-1-4939-6527-4_6.
引用本文的文献
1
Novel quinazoline-triazole-based -hydroxybenzamides/-hydroxypropenamides as HDAC inhibitors: design, synthesis, biological evaluation, and docking studies.基于喹唑啉-三唑的新型羟基苯甲酰胺/羟基丙烯酰胺作为组蛋白去乙酰化酶（HDAC）抑制剂：设计、合成、生物学评价及对接研究
RSC Adv. 2025 Jul 22;15(32):26201-26215. doi: 10.1039/d5ra04193g. eCollection 2025 Jul 21.
2
Comorbidity of lung cancer and chronic obstructive pulmonary disease: correlation and optimization of treatment strategies.肺癌与慢性阻塞性肺疾病的共病：相关性及治疗策略的优化
Transl Lung Cancer Res. 2025 Jun 30;14(6):2296-2308. doi: 10.21037/tlcr-2025-480. Epub 2025 Jun 13.
3
Recent Insights Into Breast Cancer: Molecular Pathways, Epigenetic Regulation, and Emerging Targeted Therapies.乳腺癌的最新见解：分子途径、表观遗传调控及新兴靶向治疗
Breast Cancer (Auckl). 2025 Jul 13;19:11782234251355663. doi: 10.1177/11782234251355663. eCollection 2025.
4
Expression, purification, and crystallization of "humanized" Danio rerio histone deacetylase 10 "HDAC10", the eukaryotic polyamine deacetylase.真核多胺脱乙酰酶“人源化”斑马鱼组蛋白脱乙酰酶10（HDAC10）的表达、纯化及结晶
Methods Enzymol. 2025;715:19-40. doi: 10.1016/bs.mie.2025.01.074. Epub 2025 Feb 11.
5
Histone modifications and metabolic reprogramming in tumor-associated macrophages: a potential target of tumor immunotherapy.肿瘤相关巨噬细胞中的组蛋白修饰与代谢重编程：肿瘤免疫治疗的潜在靶点
Front Immunol. 2025 May 1;16:1521550. doi: 10.3389/fimmu.2025.1521550. eCollection 2025.
6
The Role of the Sirtuin Family Histone Deacetylases in Acute Myeloid Leukemia-A Promising Road Ahead.沉默调节蛋白家族组蛋白去乙酰化酶在急性髓系白血病中的作用——前路光明。
Cancers (Basel). 2025 Mar 17;17(6):1009. doi: 10.3390/cancers17061009.
7
Unveiling the Role of Protein Posttranslational Modifications in Glioma Prognosis.揭示蛋白质翻译后修饰在胶质瘤预后中的作用
CNS Neurosci Ther. 2025 Mar;31(3):e70330. doi: 10.1111/cns.70330.
8
Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors.新型含异羟肟酸部分的联苯化合物作为首个程序性死亡受体配体1/组蛋白去乙酰化酶1双重抑制剂的发现
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2461190. doi: 10.1080/14756366.2025.2461190. Epub 2025 Feb 6.
9
Decoding ferroptosis: transforming orthopedic disease management.解读铁死亡：变革骨科疾病管理
Front Pharmacol. 2024 Dec 6;15:1509172. doi: 10.3389/fphar.2024.1509172. eCollection 2024.
10
HDACi combination therapy with IDO1i remodels the tumor microenvironment and boosts antitumor efficacy in colorectal cancer with microsatellite stability.HDACi与IDO1i联合治疗可重塑肿瘤微环境，并增强微卫星稳定型结直肠癌的抗肿瘤疗效。
J Nanobiotechnology. 2024 Dec 16;22(1):753. doi: 10.1186/s12951-024-02936-0.
本文引用的文献
1
SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation.SIRT7 将 H3K18 去乙酰化与致癌转化的维持联系起来。
Nature. 2012 Jul 5;487(7405):114-8. doi: 10.1038/nature11043.
2
Phthalates stimulate the epithelial to mesenchymal transition through an HDAC6-dependent mechanism in human breast epithelial stem cells.邻苯二甲酸酯通过组蛋白去乙酰化酶 6 依赖的机制刺激人乳腺上皮干细胞的上皮间质转化。
Toxicol Sci. 2012 Aug;128(2):365-76. doi: 10.1093/toxsci/kfs163. Epub 2012 May 2.
3
HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer.组蛋白去乙酰化酶 1 失活诱导肝癌有丝分裂缺陷和 caspase 非依赖性自噬性细胞死亡。
PLoS One. 2012;7(4):e34265. doi: 10.1371/journal.pone.0034265. Epub 2012 Apr 4.
4
HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins.组蛋白去乙酰化酶 2 的过表达通过调节细胞凋亡和细胞周期蛋白的表达赋予人肺癌细胞致癌潜能。
J Cell Biochem. 2012 Jun;113(6):2167-77. doi: 10.1002/jcb.24090.
5
HIF2α-Sp1 interaction mediates a deacetylation-dependent FVII-gene activation under hypoxic conditions in ovarian cancer cells.缺氧条件下卵巢癌细胞中 HIF2α-Sp1 相互作用介导依赖去乙酰化的 FVII 基因激活。
Nucleic Acids Res. 2012 Jul;40(12):5389-401. doi: 10.1093/nar/gks201. Epub 2012 Mar 8.
6
Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6.三氧化二砷通过抑制组蛋白去乙酰化酶 6 的细胞质底物活性发挥抗骨髓瘤作用。
PLoS One. 2012;7(2):e32215. doi: 10.1371/journal.pone.0032215. Epub 2012 Feb 22.
7
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.肝癌的联合治疗：HDAC 抑制剂 panobinostat 与索拉非尼联合具有增效的临床前疗效。
J Hepatol. 2012 Jun;56(6):1343-50. doi: 10.1016/j.jhep.2012.01.009. Epub 2012 Feb 6.
8
HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells.HDAC5 对于着丝粒异染色质的维持是必需的，并且控制人类癌细胞的细胞周期进程和存活。
Cell Death Differ. 2012 Jul;19(7):1239-52. doi: 10.1038/cdd.2012.3. Epub 2012 Feb 3.
9
Multiple roles of class I HDACs in proliferation, differentiation, and development.I 类组蛋白去乙酰化酶在增殖、分化和发育中的多重作用。
Cell Mol Life Sci. 2012 Jul;69(13):2173-87. doi: 10.1007/s00018-012-0921-9.
10
Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.抑制 HSP90 伴侣蛋白可使巨噬细胞移动抑制因子失稳，从而抑制乳腺癌进展。
J Exp Med. 2012 Feb 13;209(2):275-89. doi: 10.1084/jem.20111117. Epub 2012 Jan 23.
Zotero 插件